For example an ongoing phase 1 study (NCT02632708) of patients with IDH1 or IDH2 mutated AML receive ivosidenib (for IDH1 mutated) or enasidenib (for IDH2 mutated) combined with standard therapy for newly diagnosed AML and can continue ivosidenib or enasidenib maintenance until relapse, unacceptable toxicity, or alloSCT. The gene discussed is IDH1; the disease is acute myeloid leukemia.